… K Bojang and T Doherty supervised recruitment, vaccination, and follow-up of study
participants, and helped plan the trial; P Milligan analysed the data and helped plan the trial; M …

We report a genome-wide association (GWA) study of severe malaria in The Gambia. The
initial GWA scan included 2,500 children genotyped on the Affymetrix 500K GeneChip, and a …

Background Malaria is a major cause of morbidity and mortality in Africa. International effort
and funding for control has been stepped up, with substantial increases from 2003 in the …

New strategies are required to identify the most important targets of protective immunity in
complex eukaryotic pathogens. Natural selection maintains allelic variation in some antigens …

INTRODUCTION Malaria parasites cause human disease by invading and replicating inside
red blood cells. In the case of Plasmodium falciparum, this can lead to severe forms of …

Background A substantial decline in malaria was reported to have occurred over several
years until 2007 in the western part of The Gambia, encouraging consideration of future …

Background Plasmodium falciparum merozoite surface protein (MSP) 3 is an asexual blood-stage
malaria vaccine candidate antigen. Sequence polymorphisms divide alleles into 2 …

The merozoite surface protein 2 (MSP2) of Plasmodium falciparum is recognized by human
antibodies elicited during natural infections, and may be a target of protective immunity. In …

Host genetic factors can confer resistance against malaria 1 , raising the question of whether
this has led to evolutionary adaptation of parasite populations. Here we searched for …

Background The Expanded Programme on Immunisation (EPI) provides an effective way of
delivering intermittent preventive treatment for malaria (IPT) to infants. However, it is …